Seres Therapeutics (MCRB) Income from Continuing Operations (2014 - 2026)
Seres Therapeutics (MCRB) posted Income from Continuing Operations of 25564000.0 for Q1 2026, down 35.03% sequentially from 18932000.0 in Q4 2025, and up 18.83% YoY from 21512336.86 in Q1 2025.
Seres Therapeutics (MCRB) Income from Continuing Operations (2014 - 2026) Analysis & Trends
Seres Therapeutics has reported Income from Continuing Operations for 13 years, with the latest figure at 25564000.0 in Q1 2026.
- Quarterly Income from Continuing Operations rose 18.83% year-over-year to 25564000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 342124000.0 (down 149.33% YoY) and the FY2025 annual result came in at 402705000.0, up 6.58% from the prior year.
- Income from Continuing Operations declined to 25564000.0 in Q1 2026 per MCRB's latest filing, from 18932000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 44422000.0 in Q2 2023 and troughed at 16473107000.0 in Q3 2022.
- A 5-year average of 1067770411.76 and a median of 46413000.0 in 2023 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2022 and 2023: Income from Continuing Operations plunged 379.31% in 2022, then jumped 104.84% in 2023.
- Over 5 years, Income from Continuing Operations stood at 60339000.0 in 2022, then gained by 13.12% to 52423000.0 in 2023, then advanced by 25.92% to 38837000.0 in 2024, then jumped by 51.25% to 18932000.0 in 2025, then sank by 35.03% to 25564000.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 25564000.0, 18932000.0, and 145157000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Seres Therapeutics | 43.87 Mn | 43.87 Mn | - | -21.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -98.45 Mn |
| Mar 31, 2026 | -25.56 Mn |
| Dec 31, 2025 | -18.93 Mn |
| Sep 30, 2025 | -145.16 Mn |
| Jun 30, 2025 | -152.47 Mn |
| Mar 31, 2025 | -31.50 Mn |
| Dec 31, 2024 | -38.84 Mn |
| Sep 30, 2024 | -33.88 Mn |
| Jun 30, 2024 | -33.00 Mn |
| Mar 31, 2024 | -36.39 Mn |
| Dec 31, 2023 | -52.42 Mn |
| Sep 30, 2023 | -46.41 Mn |
| Jun 30, 2023 | 44.42 Mn |
| Mar 31, 2023 | -73.97 Mn |
| Dec 31, 2022 | -60.34 Mn |
| Sep 30, 2022 | -16.47 Bn |
| Jun 30, 2022 | -917.06 Mn |
| Mar 31, 2022 | -57.48 Mn |
| Dec 31, 2021 | -49.69 Mn |
| Sep 30, 2021 | -19.81 Bn |